Evaluation of Doxorubicin-loaded Echogenic Macroemulsion for Targeted Drug Delivery.

IF 2.8 4区医学 Q2 PHARMACOLOGY & PHARMACY

Current drug delivery Pub Date : 2024-01-01 DOI:10.2174/1567201820666230403111118

Jong-Ryul Park, Gayoung Kim, Jongho Won, Chul-Woo Kim, Donghee Park

{"title":"Evaluation of Doxorubicin-loaded Echogenic Macroemulsion for Targeted Drug Delivery.","authors":"Jong-Ryul Park, Gayoung Kim, Jongho Won, Chul-Woo Kim, Donghee Park","doi":"10.2174/1567201820666230403111118","DOIUrl":null,"url":null,"abstract":"Background: The latest technology trend in targeted drug delivery highlights stimuliresponsive particles that can release an anticancer drug in a solid tumor by responding to external stimuli.Objective: This study aims to design, fabricate, and evaluate an ultrasound-responsive drug delivery vehicle for an ultrasound-mediated drug delivery system.Methods: The drug-containing echogenic macroemulsion (eME) was fabricated by an emulsification method using the three phases (aqueous lipid solution as a shell, doxorubicin (DOX) contained oil, and perfluorohexane (PFH) as an ultrasound-responsive agent). The morphological structure of eMEs was investigated using fluorescence microscopy, and the size distribution was analyzed by using DLS. The echogenicity of eME was measured using a contrast-enhanced ultrasound device. The cytotoxicity was evaluated using a breast cancer cell (MDA-MB-231) via an in vitro cell experiment.Results: The obtained eME showed an ideal morphological structure that contained both DOX and PFH in a single particle and indicated a suitable size for enhancing ultrasound response and avoiding complications in the blood vessel. The echogenicity of eME was demonstrated via an in vitro experiment, with results showcasing the potential for targeted drug delivery. Compared to free DOX, enhanced cytotoxicity and improved drug delivery efficiency in a cancer cell were proven by using DOX-loaded eMEs and ultrasound.Conclusion: This study established a platform technology to fabricate the ultrasound-responsive vehicle. The designed drug-loaded eME could be a promising platform with ultrasound technology for targeted drug delivery.","PeriodicalId":10842,"journal":{"name":"Current drug delivery","volume":" ","pages":"785-793"},"PeriodicalIF":2.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug delivery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1567201820666230403111118","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The latest technology trend in targeted drug delivery highlights stimuliresponsive particles that can release an anticancer drug in a solid tumor by responding to external stimuli.

Objective: This study aims to design, fabricate, and evaluate an ultrasound-responsive drug delivery vehicle for an ultrasound-mediated drug delivery system.

Methods: The drug-containing echogenic macroemulsion (eME) was fabricated by an emulsification method using the three phases (aqueous lipid solution as a shell, doxorubicin (DOX) contained oil, and perfluorohexane (PFH) as an ultrasound-responsive agent). The morphological structure of eMEs was investigated using fluorescence microscopy, and the size distribution was analyzed by using DLS. The echogenicity of eME was measured using a contrast-enhanced ultrasound device. The cytotoxicity was evaluated using a breast cancer cell (MDA-MB-231) via an in vitro cell experiment.

Results: The obtained eME showed an ideal morphological structure that contained both DOX and PFH in a single particle and indicated a suitable size for enhancing ultrasound response and avoiding complications in the blood vessel. The echogenicity of eME was demonstrated via an in vitro experiment, with results showcasing the potential for targeted drug delivery. Compared to free DOX, enhanced cytotoxicity and improved drug delivery efficiency in a cancer cell were proven by using DOX-loaded eMEs and ultrasound.

Conclusion: This study established a platform technology to fabricate the ultrasound-responsive vehicle. The designed drug-loaded eME could be a promising platform with ultrasound technology for targeted drug delivery.

查看原文本刊更多论文

用于靶向给药的负载型多柔比星回声大乳剂的评估

背景：靶向给药的最新技术趋势强调刺激性共振颗粒，这种颗粒可以通过对外界刺激的反应在实体瘤中释放抗癌药物：本研究旨在设计、制造和评估一种超声响应给药载体，用于超声介导的给药系统：方法：采用乳化方法，利用三相（脂质水溶液作为外壳、含油的多柔比星（DOX）和全氟己烷（PFH）作为超声响应剂）制成含药回声大乳剂（eME）。利用荧光显微镜研究了 eMEs 的形态结构，并利用 DLS 分析了其粒度分布。使用对比增强超声装置测量了 eME 的回声性。通过体外细胞实验，使用乳腺癌细胞（MDA-MB-231）评估了细胞毒性：结果：获得的 eME 具有理想的形态结构，在单个颗粒中同时含有 DOX 和 PFH，其大小适合增强超声响应和避免血管并发症。体外实验证明了 eME 的回声性，其结果显示了靶向给药的潜力。与游离 DOX 相比，通过使用负载 DOX 的 eMEs 和超声波，证明了在癌细胞中增强了细胞毒性并提高了给药效率：本研究建立了一种制造超声响应载体的平台技术。结论：本研究建立了制造超声响应载体的平台技术，所设计的药物负载 eME 可与超声技术相结合，成为一种前景广阔的靶向给药平台。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug delivery PHARMACOLOGY & PHARMACY-

CiteScore

5.10

自引率

4.20%

发文量

170

期刊介绍： Current Drug Delivery aims to publish peer-reviewed articles, research articles, short and in-depth reviews, and drug clinical trials studies in the rapidly developing field of drug delivery. Modern drug research aims to build delivery properties of a drug at the design phase, however in many cases this idea cannot be met and the development of delivery systems becomes as important as the development of the drugs themselves. The journal aims to cover the latest outstanding developments in drug and vaccine delivery employing physical, physico-chemical and chemical methods. The drugs include a wide range of bioactive compounds from simple pharmaceuticals to peptides, proteins, nucleotides, nucleosides and sugars. The journal will also report progress in the fields of transport routes and mechanisms including efflux proteins and multi-drug resistance. The journal is essential for all pharmaceutical scientists involved in drug design, development and delivery.